OpenAlex
PricingAboutJobs
Log inGet started
Work

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

HTML

Year: 2013
Type: article
Study design: Clinical Trial
Source: Blood
DOI: 10.1182/blood-2013-08-521468
Authors: Heinz Ludwig, Hedwig Kasparu, Clemens Leitgeb, Elisabeth Rauch, Werner Linkesch, Niklas Zojer, Richard Greil, Adelheid Seebacher, Ludek Pour, Adalbert Weißmann, Zdeněk Adam
Institutions: Wilhelminen Hospital, Krankenhaus der Elisabethinen, Medical University of Graz, Hanusch Hospital, University Hospital Brno
Language: English

Topic: Multiple Myeloma Research and Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: bendamustine, bortezomib, dexamethasone, relapsed/refractory multiple myeloma, combination chemotherapy, overall response rate, progression-free survival, overall survival, thrombocytopenia, polyneuropathy, treatment toxicity, prognostic factors
SDG: Good health and well-being

Open Access status: green

Funder: Celgene
OpenAlex ID: W2048579461
FWCI: 9.17
Cites: 29
Cited by: 107
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security